ISouth Africa Delivery, iDaily Domestic Delivery, I-European Domestic Delivery

I-Fosaprepitant dimeglumine (EMEND) ipowder

Akukho kalo
5.00 ngaphandle kwe 5 ngenxa ye 1 ireyithingi abathengi
SKU: 265121-04-8. Udidi:

I-AASraw ikunye kunye nokukwazi ukuvelisa kwigram ukuya kwinqanaba le-Fosaprepitant dimeglumine (EMEND) powder (265121-04-8), phantsi kolawulo lweCGMP kunye nolawulo lwekhwalithi ephezulu.

Fosaprepitant Dimeglumine powder ifomu yetyuwa ye-dimeglumine ye-fosaprepitant, i-soluble yamanzi, i-N-phosphorylated prodrug ye-aprepitant, ne-antiemetic. Ekuphathweni kwe-intravenous kunye nokuguqulwa ngokukhawuleza kwi-aprepitant, le njengelibophelela ngokukhethekileyo kwintlobo yomntu P / neurokinin 1 (NK1) i-receptors kwinkqubo ye-nervous central (CNS). Oku kuvimbela ukufunyanwa kwe-receptor ye-substance engapheliyo P kunye nokuvimbela imveliso ye-P-induced emesis.

Ingcaciso yeMveliso

I-Fosaprepitant dimeglumine (EMEND) ividiyo ye powder


I-Fosaprepitant dimeglumine (EMEND) ipowder Abalinganiswa basisiseko

igama: I-Fosaprepitant dimeglumine (EMEND) ipowder
CAS: 265121-04-8
I-molecular Formula: C23H22F7N4O6P.2C7H17NO5
Isisindo somzimba: 1004.83
Melt Point: 242-247 ° C
Isitoreji sokugcina: -20 ° C Ifreezer
umbala: umhlophe ukuya kumhlophe omhlophe we-amorphous powder


I-Fosaprepitant dimeglumine (EMEND) Ukusetyenziswa kwamandla

igama

I-Fosaprepitant dimeglumine powder (i-CAS 265121-04-8)

I-EMEND powder

Fosaprepitant dimeglumine Ukusetyenziswa kwamandla

Ukudibanisa nezinye i-antiemetic agents, ekuthintela i-nicea kunye nokuhlanza okubambezelekayo kunye nokuhlanza okuhambelana nokuqala nokuphindaphinda izifundo ze-chemotherapy yomdlavuza ophezulu kunye neendlela eziqhelekileyo, kuquka ne-high-dose cisplatin.

Isixwayiso kwi-EMEND powder (CAS 265121-04-8)

  • I-Fosaprepitant kufuneka isetyenziswe ngokulumkisa kwizigulane ezifumana imichiza edibeneyo ejoliswe ngokuyinhloko nge-CYP3A4.
  • Ukuphendula ngokukhawuleza kwe-hypersensitivity kungenzeka ngexesha lokunyuswa. Izigulane ngokubanzi ziphendule ukuyeka. Akukhuthazwa ukuvuselela ukumnika. (B)
  • Ukuphathwa kolawulo lwe-fosaprepitant okanye i-aprepitant kunye ne-warfarin (i-CYP2C9 substrate) inokubangela ukuhla kweempawu zonyango kwi-International Normalized Ratio (INR) yexesha leprothrombin. (C)
  • Ukusebenza kwee-contraceptive ze-hormonal ngexesha kunye neentsuku ze-28 emva kweqondo lokugcina le-fosaprepitant okanye i-aprepitant lingancitshiswa. Ezinye iindlela zokubuyisela ukukhulelwa kufuneka zisetyenziswe. (D)

A: I-CYP3A4 Ukusebenzisana kweFosaprepitant iguqulwa ngokukhawuleza ibe yi-aprepitant, eyi-inhibitor e-moderation ye-CYP3A4 xa ilawulwa njenge-regimen ye-antiemétique ye-XMUMX ye-CINV. I-Fosaprepitant kufuneka isetyenziswe ngokuqaphela kwizigulane ezithobela amayeza adibeneyo ngokubhekiselele kwi-CYP3A3. Ukuvinjelwa kwe-CYP4A3 nge-aprepitant okanye i-fosaprepitant kungaholela kwiziphumo eziphezulu ze-plasma zala mayeza. Xa i-fosaprepitant isetyenziselwa i-CYP4A3 inhibitor, i-aprepitant plasm concentrations ingaphakanyiswa. Xa i-aprepitant isetyenziselwa ukudibanisa kunye nemishanguzo eyenza umsebenzi we-CYP4A3, i-aprepitant plasm concentrations ingancitshiswa, kwaye oku kungakhokelela ekunciphiseni ukusebenza kwe-aprepitant. I-agents ze-Chemotherapy ezaziwa ngokuba zi-metabolized by CYP4A3 ziquka i-docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine kunye ne-vincristine. Kwizifundo zeklinikhi, i-regimen yomlomo i-aprepitant ilawulwa ngokuqhelekileyo nge-etoposide, vinorelbine, okanye paclitaxel. Amanqanaba ala ma-agent awazange ahlengahlengiswe kwi-akhawunti yezinto ezinokusetyenziswa kwamachiza. Kwizifundo ezihlukeneyo ze-pharmacokinetic, akukho tshintsho oluphawulekayo lwekliniki kwi-docetaxel okanye i-vinorelbine pharmacokinetics yabonwa xa i-regenen yomlomo eyayilawulwa yi-aprepitant. Ngenxa yenani elincinane lezigulane kwizifundo zonyango ezithole i-CYP4A3 substrates i-vinblastine, i-vincristine, okanye i-ifosfamide, ilumkiso kunye nokubeka iliso ngokucetyiswayo kwizigulane ezifumana ezi arhente okanye ezinye i-agents ze-chemotherapy zichithwe ngokubanzi yi-CYP4A3 ezingakhange zifundwe.
B: Ukuphendula kwe-Hypersensitivity Isolated imibiko yeempendulo ezixhomekeke kwi-hypersensitive response, kuquka ukutshitshiswa, i-erythema, i-dyspnea kunye ne-anaphylaxis zenzeke ngexesha lokunyuka kwe-fosaprepitant. Ezi mpendulo ze-hypersensitivity ziye zaphendula ngokukhawuleza ukuxothwa kunye nokulawulwa kweyeza ezifanelekileyo. Ukubuyiswa kwakhona kwe-infusion akukhuthazwa kwizigulane ezifumana ezi zimpawu ngexesha lokusebenzisa okokuqala.
C: Ulawulo kunye ne-Warfarin Ulawulo lwe-fosaprepitant okanye i-aprepitant kunye ne-warfarin lungakhokelela ekunciphiseni okwenyuka kliniki kwi-International Normalized Ratio (INR) yexesha le-prothrombin. Kwizigulane zonyango olungapheliyo lwe-warfarin, i-INR kufuneka ihlolwe ngokukhawuleza kwixesha le-2-iveki, ngokukodwa kwi-7 kwiintsuku ze-10, emva kokuqaliswa kwe-fosaprepitant kunye nomjikelezo ngamnye we-chemotherapy.
D. Ulawulo olusebenzayo kunye neCommonceptive Hormonal Ulawulo olusebenzayo kunye ne-fosaprepitant okanye i-aprepitant, ukuphumelela kwe-contraceptive ye-hormonal kuyancitshiswa ngexesha kunye neentsuku ze-28 emva kwesilinganiso sokugqibela se-fosaprepitant okanye i-aprepitant. Iinkqubo zokunqanda ukukhulelwa kufuneka zisebenzise ngexesha lonyango kunye neenyanga ze-1 ezilandelayo kwimizuzu yokugqibela ye-fosaprepitant okanye i-aprepitant [Jonga ukusebenzisana kwezidakamizwa]. I-5.5 Isigxina esingapheliyo Ukusetyenziswa okungapheliyo Ukusetyenziswa okuqhubekayo kwe-EMEND powder ye-Injection yokuthintela isicupunu kunye nokuhlanza akukhuthazwa ngenxa yokuba ingafundwanga; kwaye ngenxa yeprofayile yokusebenzisana neziyobisi ingatshintsha ngexesha lokusetyenziswa okungapheliyo.

I mi yalelo

I-Fosaprepitant dimeglumine powder yomjovo i-150 mg ibonakaliswe kubantu abadala ngokudibanisa nezinye i-antiemetic agents ukwenzela ukuthintela ukulibaziseka kwesoxiso kunye nokuhlanza okuhambelana nokuqala nokuphindaphinda izifundo ze-MEC. Imilinganiselo evumelekileyo kubantu abadala i-150-mg intravenous (IV) yokunyuswa kwe-20 kumzuzu we-30 malunga nemizuzu eyi-30 ngaphambi kwe-chemotherapy ngosuku lwe-1. Ukuvunyelwa kwe-FDA kwesi sibonakaliso esitsha sisekelwe kwinxalenye yeziphumo ezivela kwi-random, efanayo, i-doubleblind, eqhutywe isifundo esilawulwa yinkomfa eyenza i-fosaprepitant ye-injection njenge-infusion yangaphakathi kunye ne-ondansetron ne-dexamethasone (ebizwa ngokuba yi-EMEND powder regimen ) (N = 502) xa kuthelekiswa ne-ondansetron kunye ne-dexamethasone yedwa (i-regimen yokulawula) (N = 498) kwizigulane ezifumana uMphathiswa. Iiphelo eziphambili ziyimpendulo epheleleyo (ichazwe ngokungabikho ukuhlanza kunye nokusetyenziswa konyango lokunceda) kwisigaba sokulibaziseka (i-25 ukuya kwii-120 iiyure emva kokuqaliswa kwe-chemotherapy) ye-cerebral-provoked nausea kunye nokuhlanza. I-78.9% yezinga lokuphendula elipheleleyo ligcinwe kunye neFosaprepitant dimeglumine powder regimen xa kuthelekiswa ne-68.5% kunye ne-regimen yolawulo (P <0.001). Iimpembelelo eziqhelekileyo eziphambili ezichazwe kwi-EMEND powder regimen kunye ne-regimen yokulawula ziyakhathala (15% vs 13%), isifo sohudo (13% vs 11%), i-neutropenia (8% vs 7%), asthenia (4% vs 3%) , i-nemia (3% vs 2% intlungu ekupheleni (3% vs 2%).

Inkcazo yeFosaprepitant dimeglumine powder ye-injection, ngokunxulumene nezinye i-antiemetic agents, iboniswa kubantu abadala ukukhusela ukukhwabanisa kunye nokulibaziseka okukhulu kunye nokuhlanza okuhambelana nokuqala nokuphindaphinda izifundo ze-chemotherapy ephezulu emetogenic, okubandakanya i-cisplatin enkulu-dose; kunye nokuthintela ukulibaziseka kwesohlwayo kunye nokuhlanza okuhambelana nokuqala nokuphindaphinda izifundo ze-chemotherapy yomhlaza emetogenic.

I-Fosaprepitant dimeglumine powder ye-injection ayizange ifundwe kunyango lwe-nausea kunye nokuhlanza.

I-Fosaprepitant dimeglumine I-Raw Powder (i-CAS 265121-04-8)

I-10grams encinci.
Uphando malunga nobukhulu obuqhelekileyo (ngaphakathi kwe-1kg) lungathunyelwa kwiiyure ze-12 emva kokuhlawula.
Ukwenza umlinganiselo omkhulu (ngaphakathi kwe-1kg) ungathunyelwa kwimihla yokusebenza ye-3 emva kokuhlawula.

I-Fosaprepitant dimeglumine yePowder Marketing

Ukubonelelwa kwikamva elizayo.


Indlela yokuthenga iFosaprepitant dimeglumine powder: Thenga i-EMEND powder esuka kwi-AASraw

1.Qhagamshelana nathi nge-imeyile yethu inkqubo yophando, okanye i-skype ye-intanethiummeli wenkonzo yamakhasimende (CSR).
2.Ukusibonelela ngobuninzi bakho kunye neadesi.
I-3.I-CSR yethu iya kukunika isingeniso, ixesha lokuhlawula, inombolo yokulandelela, iindlela zokuhambisa kunye nomhla wokufika oqikelelwayo (i-ETA).
I-4.Inkokhelo eyenziwe kwaye iimpahla ziya kuthunyelwa kwiiyure ze-12 (Ukuze ulandelwe ngaphakathi kwe-10kg).
5.Goods zifunyenwe kwaye zinike izimvo.


=

IAAA

I-COA 265121-04-8 I-Fosaprepitant dimeglumine (EMEND) i-powder AASRAW

HNMR

SiyiFosaprepitant dimeglumine powder supplie, i-EMEND powder yokuthengisa, iFosaprepitant dimeglumine (EMEND) powder (265121-04-8) ≥98% | AASraw

Recipes

I-Fosaprepitant dimeglumine Ukupheka kweePowula eziNinzi:

Ukubuza ummeli wethu ummeli (Representative Representative) (CSR) ngeenkcukacha, ngokubhekiselele kuyo.

Iziqulatho kunye nokuqulunqwa kwemveliso

I-Fosaprepitant Dimeglumine isebenzisa unyango lweziyobisi zamachiza

ngokutsha 1 ngenxa I-Fosaprepitant dimeglumine (EMEND) ipowder

  1. ikaliwe 5 ngaphandle 5

    Aasraw -

    I-Fosaprepitant dimeglumine (EMEND) i powder iyinhlakanipho

Yongeza kwakhona

Idilesi yakho ye email aziyi kupapashwa. amasimi ezifunekayo ziphawulwa *